Dark, Then Dawn: ANDA Workload Approaching Steady State After 2014 Eruption
Executive Summary
FDA Office of Generic Drugs' output is beginning to compete with, rather than be overwhelmed by, sponsors' input.
You may also be interested in...
Generic Drug Review: US FDA Approves More ANDAs Than It Receives For First Time Since Early 2016
Among the 61 approvals in February appear to be ANDAs from the official GDUFA backlog, which have been pending for more than four years.
Generic Drug Review: US FDA Approves More ANDAs Than It Receives For First Time Since Early 2016
Among the 61 approvals in February appear to be ANDAs from the official GDUFA backlog, which have been pending for more than four years.
Generic Drug Review At US FDA: Has Submission Rush Ended Or Just Paused?
Excitement to get a 10-month ANDA review may have waned in January as submissions plummet, but can approvals keep up?